Exodus Point Capital Management, LP Cullinan Oncology, Inc. Transaction History
Exodus Point Capital Management, LP
- $11.4 Billion
- Q2 2025
A detailed history of Exodus Point Capital Management, LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 13,988 shares of CGEM stock, worth $101,692. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,988
Previous 35,200
60.26%
Holding current value
$101,692
Previous $266,000
60.53%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CGEM
# of Institutions
152Shares Held
68.4MCall Options Held
15.6KPut Options Held
17.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$55.6 Million10.72% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$41.8 Million1.91% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$28.1 Million0.74% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$25.8 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$24.8 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $332M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...